A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria

Condition:   Malaria Interventions:   Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD;   Drug: Sodium ferrous citrate (SFC) 472 mg QD;   Drug: Artemisinin-based combination (ACT);   Drug: Placebo;   Drug: 5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID;   Drug: Sodium ferrous citrate (S FC) 236 mg BID Sponsors:   Neopharma Japan Co., Ltd.;   Parexel Not yet recruiting

Source: ClinicalTrials.gov - July 16, 2019 Category: Research Source Type: clinical trials